Document is current

Article History

Received: 5 February 2022

Accepted: 31 March 2022

First Online: 23 April 2022

Declarations

:

: B.M.L.: has received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB; has received grants from and/or has been speaker for: Abiogen, Alexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, UCB; has been consultant for: Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB; C.A.M.: has been consultant for Analysis Group Inc (USA), Ipsen S.p.A., IQVIA RDS Switzerland, Medpace Clinical Research (USA), Novartis Farma S.p.A., Novartis Pharma Services AG (Dubai), Novo Nordisk S.p.A., Ipsen Korea, Pfizer Italia S.r.l; C.L.: received lecture fees from Abiogen Pharma, Sandoz and Metagenics and previously consulted for UCB Pharma, is a member of the Editorial Board of the Journal of Endocrinological Investigation; M.C.: has participated as advisory board: Abiogen Pharma, received grant support from: Shire/Takeda; has participated in research trials: Ascendis Pharma, Horizon Pharma; M.G.: has previously consulted for Shire/Takeda, Recordati, Novartis, Pfizer, received lecture fees from Recordati; C.F.: is a member of the Editorial Board of the Journal of Endocrinological Investigation. Other authors have nothing to declare.

: The study was approved by the Institutional Review Board of University Hospital Careggi of Florence, Italy (number: 10641_oss; 16 May 2017). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

: Informed consent was obtained from all individual participants included in the study.

: The study was approved by our local ethical committee and informed consent was obtained.